Literature DB >> 14715799

Efficacy of galactomannan antigen in the Platelia Aspergillus enzyme immunoassay for diagnosis of invasive aspergillosis in liver transplant recipients.

Eun Jeong Kwak1, Shahid Husain, Asia Obman, Lisa Meinke, Janet Stout, Shimon Kusne, Marilyn M Wagener, Nina Singh.   

Abstract

The utility of galactomannan antigen for diagnosing invasive aspergillosis was evaluated in 154 liver transplant recipients. Sample agreement was 98.5%, and patient specificity was 87%. Galactomannan positivity correlated with mortality, even when controlled for the number of tests performed. Whether galactomannan positivity identifies a subgroup at risk for poor outcome warrants further evaluation.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14715799      PMCID： PMC321718          DOI： 10.1128/JCM.42.1.435-438.2004

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  7 in total

Review 1.  Invasive aspergillosis in transplant recipients.

Authors:  D L Paterson; N Singh
Journal:  Medicine (Baltimore)       Date:  1999-03       Impact factor: 1.889

2.  False-positive results of Aspergillus enzyme-linked immunosorbent assay in a patient with chronic graft-versus-host disease after allogeneic bone marrow transplantation.

Authors:  T Hamaki; M Kami; Y Kanda; S Miyakoshi; J Ueyama; S Morinaga; Y Mutou
Journal:  Bone Marrow Transplant       Date:  2001-09       Impact factor: 5.483

3.  Tolerogenic immunosuppression for organ transplantation.

Authors:  Thomas E Starzl; Noriko Murase; Kareem Abu-Elmagd; Edward A Gray; Ron Shapiro; Bijan Eghtesad; Robert J Corry; Mark L Jordan; Paulo Fontes; Tim Gayowski; Geoffrey Bond; Velma P Scantlebury; Santosh Potdar; Parmjeet Randhawa; Tong Wu; Adriana Zeevi; Michael A Nalesnik; Jennifer Woodward; Amadeo Marcos; Massimo Trucco; Anthony J Demetris; John J Fung
Journal:  Lancet       Date:  2003-05-03       Impact factor: 79.321

4.  Invasive aspergillosis in liver transplant recipients in the 1990s.

Authors:  N Singh; P M Arnow; A Bonham; E Dominguez; D L Paterson; G A Pankey; M M Wagener; V L Yu
Journal:  Transplantation       Date:  1997-09-15       Impact factor: 4.939

5.  Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.

Authors:  S Ascioglu; J H Rex; B de Pauw; J E Bennett; J Bille; F Crokaert; D W Denning; J P Donnelly; J E Edwards; Z Erjavec; D Fiere; O Lortholary; J Maertens; J F Meis; T F Patterson; J Ritter; D Selleslag; P M Shah; D A Stevens; T J Walsh
Journal:  Clin Infect Dis       Date:  2001-11-26       Impact factor: 9.079

6.  Increased incidence of chronic rejection in adult patients transplanted for autoimmune hepatitis: assessment of risk factors.

Authors:  P Milkiewicz; B Gunson; S Saksena; M Hathaway; S G Hubscher; E Elias
Journal:  Transplantation       Date:  2000-08-15       Impact factor: 4.939

7.  Receptor-mediated clearance of Aspergillus galactomannan.

Authors:  J E Bennett; M M Friedman; B Dupont
Journal:  J Infect Dis       Date:  1987-05       Impact factor: 5.226
  7 in total
  21 in total

1.  Development of monoclonal antibody-based galactomannoprotein antigen-capture ELISAs to detect Aspergillus fumigatus infection in the invasive aspergillosis rabbit models.

Authors:  Z-Y Wang; J-P Cai; L-W Qiu; W Hao; Y-X Pan; E T K Tung; C C Y Lau; P C Y Woo; S K P Lau; K-Y Yuen; X-Y Che
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-06-05       Impact factor: 3.267

Review 2.  Aspergillus infections in transplant recipients.

Authors:  Nina Singh; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

3.  Invasive aspergillosis in the ICU: an emerging disease.

Authors:  Wouter Meersseman; Eric Van Wijngaerden
Journal:  Intensive Care Med       Date:  2007-07-24       Impact factor: 17.440

4.  Prophylaxis of invasive mycoses in solid organ transplantation.

Authors:  Kyle P Radack; Barbara D Alexander
Journal:  Curr Infect Dis Rep       Date:  2009-11       Impact factor: 3.725

5.  The Role of Biomarkers for Diagnosis of and Therapeutic Decisions Related to Invasive Aspergillosis in Children.

Authors:  Brian T Fisher
Journal:  Curr Fungal Infect Rep       Date:  2013-03-01

6.  Updated guidelines for the diagnosis and management of aspergillosis.

Authors:  Elizabeth Ann Misch; Nasia Safdar
Journal:  J Thorac Dis       Date:  2016-12       Impact factor: 2.895

Review 7.  [Update: invasive fungal infections: Diagnosis and treatment in surgical intensive care medicine].

Authors:  C Lichtenstern; S Swoboda; M Hirschburger; E Domann; T Hoppe-Tichy; M Winkler; C Lass-Flörl; M A Weigand
Journal:  Anaesthesist       Date:  2010-01       Impact factor: 1.041

8.  Detection of galactomannan antigenemia in patients receiving piperacillin-tazobactam and correlations between in vitro, in vivo, and clinical properties of the drug-antigen interaction.

Authors:  Thomas J Walsh; Shmuel Shoham; Ruta Petraitiene; Tin Sein; Robert Schaufele; Amy Kelaher; Heidi Murray; Christine Mya-San; John Bacher; Vidmantas Petraitis
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

9.  Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Thomas F Patterson; George R Thompson; David W Denning; Jay A Fishman; Susan Hadley; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; M Hong Nguyen; Brahm H Segal; William J Steinbach; David A Stevens; Thomas J Walsh; John R Wingard; Jo-Anne H Young; John E Bennett
Journal:  Clin Infect Dis       Date:  2016-06-29       Impact factor: 9.079

10.  Use of bronchoalveolar lavage to detect galactomannan for diagnosis of pulmonary aspergillosis among nonimmunocompromised hosts.

Authors:  M Hong Nguyen; Reia Jaber; Helen L Leather; John R Wingard; Benjamin Staley; L Joseph Wheat; Christina L Cline; Maher Baz; Kenneth H Rand; Cornelius J Clancy
Journal:  J Clin Microbiol       Date:  2007-06-27       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.